Macroaxis: Personalized Investing
Simple Personalized Investing

FNMFO FNMFO 096770 KDDIF Insurance Commodities Health Management Banks 
Benchmark SP 500  1,650   0.91  Index Moved Down -0.06% ...


Processing
Collecting data for MDGN

Medgenics quote and profile

 
 Companies |  Insiders  | Dashboard  
     
4.1
  
STOCK
(0.06)  Macroaxis: -1.44 Down   1.44%  
Year To Date
3.6616.43
Last 1 Month(s)
3.884.32
Trading Day 
3.874.17
May 24 2013 

Diversification Suggestion

Use Medgenics to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly
Analyze Medgenics Inc Trend or Check current 30 days Medgenics correlation with market (S&P 500)
1 Month Beta 0.41  
Highest Price:  
Lowest Price:  
4.32  
3.88  
May 16 2013 
May 08 2013 
As returns on market increase, Medgenics returns are expected to increase less than the market. However during bear market, the loss on holding Medgenics will be expected to be smaller as well.
Medgenics Inc Small BetaMedgenics Inc Beta Legend
MDGN United States AMEX
Medgenics Inc
Benchmark S&P 500
http://www.medgenics.com
Contact Number: 415. 568. 2245
Currency: USD - US Dollar
Traded on American Stock Exchange
    
Current Valuation39.43 M
Shares Outstanding18.48 M
Number of Shares Shorted359.17 K
Cash and Equivalents32.46 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.00 % No Change  
 United States SP 500   0.06 % Macroaxis: 0.06 Moved Down  
 
 United States NYSE   0.25 % Macroaxis: 0.25 Moved Down  
 
 thisRed MDGN MDGN agains markets  1.44 % Macroaxis: change 1.44 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Medgenics Leadership

Andrew Pearlman Founder, CEO and President and Director, Ph.D
Sol Barer Chairman of the Board
Eugene Bauer Executive Chairman of the Board
Stephen Bellomo VP - Program Management and Product Development; COO of Medgenics Medical (Israel) Limited

Medgenics Price and Market Media

The median price of Medgenics for the period between Wed, Apr 24, 2013 and Fri, May 24, 2013 is 4.1 with a coefficient of variation of 3.15. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 4.11, and mean deviation of 0.11. The Stock received some media coverage during the period.
Medgenics         SP 500
Price Growth (%)
 
1
MEDGENICS INC. Medgenics Reports Positive Interim Results fr...04/26/2013Macroaxis: News
2
MEDGENICS INC. Medgenics Announces Results of 2013 Annual Me...05/02/2013Macroaxis: News
3
MEDGENICS INC. Medgenics Reports First Quarter 2013 Financia...05/10/2013Macroaxis: News

Medgenics Summary

Medgenics Inc [MDGN] is traded on American Stock Exchange in USA. It is located in Medgenics, Inc.San Francisco, CA and employs 34 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 71.89 M. Medgenics Inc has 18.48 M outstanding shares of which 359.17 K shares are now shorted by private and institutional investors with about 7.3 trading days to cover.
Medgenics, Inc., a medical technology and therapeutics company, engages in the research and development of solutions in the field of biotechnology and associated medical equipment in the United States. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
96 %
 
Follow Medgenics with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Medgenics to your reader
 

Medgenics Research Report

Medgenics vs. Federal

Correlation analysis and fundamentals comparison between Medgenics Inc and Federal National Mor

Medgenics Executives

Stephen Bellomo VP - Program Management and Product Development; COO of Medgenics Medical (Israel) Limited
Clarence Dellio COO

Medgenics Directors

Joseph Grano Director, Ph.D
Alastair Clemow Independent Director, MBA
Stephen McMurray Non-Executive Independent Director
Isaac Blech Director
Phyllis Bellin Treasurer, Corporate Secretary, Director - Finance and Administration, MBA

Medgenics Management

Marvin MD Chief Medical Officer
Marvin Garovoy Chief Medical Officer

Medgenics Fundamentals

Shares Outstanding vs Return On Asset
Beta vs Return On Equity
Shares Outstanding vs Cash Flow from Operations
Current Ratio vs Return On Equity

Medgenics vs Competition

Medgenics vs. Federal National Mortgage Association
Medgenics vs. Federal National Mortgage Association
Medgenics vs. SK Innovation
Medgenics vs. KDDI Corp
Medgenics vs. Japan Tobacco Inc
Medgenics vs. Inpex Corporation
Medgenics vs. AP M
Medgenics vs. AP M
Medgenics vs. Citigroup Inc
Medgenics vs. Akbank TAS

Medgenics May 24 2013 Opportunity Range

Downside Deviation1.87
Information Ratio(0.09)
Maximum Drawdown7.33
Value At Risk(2.51)
Potential Upside5.12

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium